Pfizer/Aventis File For Exubera In Europe; No Timeline Yet On U.S. Submission

With extensive use of inhaled insulin expected "right out of the box," the development partners are focused on getting Exubera through, not to, regulatory agencies as quickly as possible, Pfizer CFO Shedlarz says.